SCHEMBL2300697

SCHEMBL2300697

Cc1ccc(-c2nc(NC(=O)c3ccc(Cl)nc3)sc2C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
POLB P06746 3/20 0.59
NPC1 O15118 3/20 0.59
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 5/20 0.56
LMNA P02545 3/20 0.56
KDM4E B2RXH2 1/20 0.56
PLTP P55058 1/20 0.56
MAPT P10636 3/20 0.53
PKM P14618 2/20 0.53
ADORA3 P0DMS8 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
BLM P54132 1/20 0.50
S1PR4 O95977 1/20 0.50
ADRB2 P07550 1/20 0.50
S1PR1 P21453 1/20 0.50
NOD2 Q9HC29 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303467 0.93 RAB9A (0.59) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2301495 0.91 ALDH1A1 (0.62) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2302150 0.91 ALDH1A1 (0.68) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2303062 0.89 MAPT (0.55) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2305088 0.84 RAB9A (0.55) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2753568 0.80 ADORA3 (0.73) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL2304917 0.80 ALDH1A1 (0.84) RAB9APOLBNPC1KMT2AMEN1
SCHEMBL837913 0.80 ALDH1A1 (0.66) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL12248995 0.79 LMNA (0.61) RAB9ASMN1; SMN2POLBNPC1KMT2A
SCHEMBL12248902 0.78 MAPT (0.61) RAB9ASMN1; SMN2POLBNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 RAB9A 2586/4885SMN1; SMN2 4749/4885POLB 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.